By Colin Kellaher
Nurix Therapeutics has widened its collaboration with Sanofi, granting the French pharmaceutical company an exclusive license to an undisclosed program targeting a previously undruggable transcription factor for autoimmune diseases.
Nurix on Wednesday said it received a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount the San Francisco clinical-stage biopharmaceutical company has received to date under the pact to $105 million.
Nurix said the new collaboration target is a central regulator of the inflammation response and is distinct from the companies' existing STAT6 degrader program.
Nurix said it remains eligible for up to $465 million in development, regulatory and commercial milestone payments per licensed program under its work with Sanofi, as well as royalties on future sales.
Shares of Nurix were recently up 3.1% to $10.79 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 02, 2025 07:33 ET (11:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。